Boxer Capital, LLC

Insider Reports History

Location
San Diego, CA
Signature
/s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Boxer Capital, LLC:

Company Role Class Num Shares Value Price $ Report Date Ownership
Tyra Biosciences, Inc. Other* Common Stock 6,448,359 $83,893,151 $13.01 06 Feb 2024 Direct
Tango Therapeutics, Inc. Other* Common Stock 8,198,642 $68,798,084 $8.39 16 Oct 2023 Direct
Tango Therapeutics, Inc. Other* Common Stock 6,988,450 $58,642,879 $8.39 13 Oct 2023 Indirect
iTeos Therapeutics, Inc. Other* Common Stock 2,946,915 $51,571,013 $17.50 10 May 2024 Direct
Tango Therapeutics, Inc. Other* Prefunded Warrant 2,340,579 $12,053,748 $5.15 11 Aug 2023 Direct
Tyra Biosciences, Inc. Other* Warrant (right to purchase) 705,280 $9,174,988 $13.01 06 Feb 2024 Direct
Odonate Therapeutics, Inc. 10%+ Owner Common Stock 4,207,086 $6,541,598 $1.55 24 Nov 2021 Direct
Rain Oncology Inc. Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. Common Stock 1,152,212 $1,394,177 $1.21 22 May 2023 Direct
Tyra Biosciences, Inc. Other* Common Stock 85,939 $1,118,066 $13.01 06 Feb 2024 Indirect
Mirati Therapeutics, Inc. Other* Common Stock 0 $59.02 23 Jan 2024 Direct
Mirati Therapeutics, Inc. Other* Common Stock 0 $59.02 23 Jan 2024 Indirect
Mirati Therapeutics, Inc. Other* Warrant (right to purchase) 0 23 Jan 2024 Direct
Mirati Therapeutics, Inc. Other* Warrant (right to purchase) 0 23 Jan 2024 Indirect

Insider Reports Filed by Boxer Capital, LLC

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ITOS iTeos Therapeutics, Inc. 10 May 2024 1 +$19,999,998 4 Other* 14 May 2024, 21:32
TYRA Tyra Biosciences, Inc. 06 Feb 2024 2 +$9,999,978 4 Other* 08 Feb 2024, 17:09
/report/000089534524000019-boxer-capital-llc-2024-01-23 Mirati Therapeutics, Inc. 23 Jan 2024 8 $0 4 Other* 25 Jan 2024, 16:32
TNGX Tango Therapeutics, Inc. 13 Oct 2023 2 +$8,722,500 4/A Other* 17 Oct 2023, 19:41
TNGX Tango Therapeutics, Inc. 09 Oct 2023 2 -$2,240,250 4 Other* 11 Oct 2023, 21:22
ITOS iTeos Therapeutics, Inc. 23 Aug 2023 3 -$5,692,673 4 Other* 25 Aug 2023, 22:28
TNGX Tango Therapeutics, Inc. 11 Aug 2023 2 +$14,499,998 4/A Director, Other* 11 Oct 2023, 19:22
/report/000089534523000500-boxer-capital-llc-2023-08-11 Mirati Therapeutics, Inc. 11 Aug 2023 2 +$34,999,449 4 Other* 15 Aug 2023, 22:39
/report/000089534523000499-boxer-capital-llc-2023-08-11 Mirati Therapeutics, Inc. 11 Aug 2023 2 +$34,999,449 4 Other* 15 Aug 2023, 22:38
/report/000089534523000356-boxer-capital-llc-2023-05-22 Rain Oncology Inc. 22 May 2023 1 -$1,243,750 4 Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. 24 May 2023, 20:05
TNGX Tango Therapeutics, Inc. 11 Oct 2022 3 +$1,044,573 4 10%+ Owner 13 Oct 2022, 21:30
TNGX Tango Therapeutics, Inc. 04 Oct 2022 4 +$714,096 4 10%+ Owner 06 Oct 2022, 21:15
ITOS iTeos Therapeutics, Inc. 17 Mar 2022 1 -$20,275,835 4 10%+ Owner 18 Mar 2022, 21:00
ITOS iTeos Therapeutics, Inc. 03 Jan 2022 14 -$32,575,642 4 Director, 10%+ Owner 05 Jan 2022, 20:20
TYRA Tyra Biosciences, Inc. 17 Dec 2021 1 +$1,640,312 4 10%+ Owner 21 Dec 2021, 16:00
/report/000089924321046083-boxer-capital-llc-2021-11-22 Odonate Therapeutics, Inc. 22 Nov 2021 2 -$623,340 4 10%+ Owner 24 Nov 2021, 17:00
/report/000089924321045437-boxer-capital-llc-2021-11-17 Odonate Therapeutics, Inc. 17 Nov 2021 3 -$2,062,775 4 Director, 10%+ Owner 19 Nov 2021, 18:21
TYRA Tyra Biosciences, Inc. 17 Sep 2021 7 +$10,000,000 4 10%+ Owner 17 Sep 2021, 16:38
TYRA Tyra Biosciences, Inc. 14 Sep 2021 0 $0 3 10%+ Owner 14 Sep 2021, 21:14
TNGX Tango Therapeutics, Inc. 10 Aug 2021 0 $0 3 10%+ Owner 20 Aug 2021, 16:30